AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 32247315
Drug: Control (normal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (normal saline lubrication without BH spray)
Trial: 33107977
Drug: Tissue level
RxNorm normalized name: tissue respiratory factor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tissue level implants with a partially smooth collar in thin phenotype group (n=13)
Trial: 33107977
Drug: Tissue level
RxNorm normalized name: tissue respiratory factor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tissue level implants with a partially smooth collar in thick phenotype group (n=13)
Trial: 36195338
Drug: LYS006 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LYS006 5 mg once daily
Trial: 36195338
Drug: LYS006 15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LYS006 15 mg once daily
Trial: 36195338
Drug: LYS006 20-80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LYS006 20-80 mg twice a day
Trial: 36195338
Drug: LYS006 (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LYS006 (various doses)
Trial: 35317736
Drug: Control treatment
RxNorm normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control treatment (Observation of naturalistic scenes + Virtual Reality) (CO + VR)
Trial: 32054536
Drug: High-dose rifampicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose rifampicin (35 mg/kg) alongside standard TB treatment
Trial: 32054536
Drug: Standard-dose rifampicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose rifampicin alongside standard TB treatment
Trial: 34105866
Drug: Alpha-lipoic acid
RxNorm normalized name: Alpha-lipoic acid
DrugBank: Lipoic acid (DB00166)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alpha-lipoic acid (ALA) 300 mg capsule twice daily for 3 months
Trial: 33185376
Drug: 30 mL
RxNorm normalized name: Vial M/T 30 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mL 0.5% bupivacaine at 23°C
Trial: 33185376
Drug: 30 mL
RxNorm normalized name: Vial M/T 30 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mL 0.5% bupivacaine warmed to 37°C
Trial: 35803088
Drug: 600mg lavender
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600mg lavender flowers capsules, taken three times daily for 60 days
Trial: 35803088
Drug: 600mg cornstarch
RxNorm normalized name: cornstarch
DrugBank: Starch, corn (DB11599)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600mg cornstarch capsules, taken three times daily for 60 days
Trial: 32773737
Drug: General anesthesia
RxNorm normalized name: Ethers for general anesthesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General anesthesia (GA) and postoperative intravenous analgesia (Group A)
Trial: 32773737
Drug: General anesthesia
RxNorm normalized name: Ethers for general anesthesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General anesthesia (GA) combined with thoracic epidural anesthesia (TEA) and postoperative intravenous analgesia (Group C)
Trial: 34128083
Drug: Rivaroxaban (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivaroxaban (2.5 mg bid)
Trial: 36368677
Drug: Isomyosamine 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isomyosamine 150 mg, 300 mg, 450 mg (single daily doses for 3 days)
Trial: 36368677
Drug: Isomyosamine 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isomyosamine 600 mg (multiple daily doses for 6 days)
Trial: 36368677
Drug: Isomyosamine (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isomyosamine (various doses)
Trial: 36368677
Drug: Isomyosamine 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isomyosamine 300 mg to 600 mg (single dose)
Trial: 36368677
Drug: Isomyosamine 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isomyosamine 600 mg (once daily for 5 days)
Trial: 36368677
Drug: Isomyosamine (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isomyosamine (all doses)
Trial: 33491389
Drug: PerioTabs (NitrAdine-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PerioTabs (NitrAdine-based gingiva brushing solution) for 10 days
Trial: 35684144
Drug: HMB-enriched oral
RxNorm normalized name: petrolatum
DrugBank: Petrolatum (DB11058)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HMB-enriched oral nutritional supplement (1.5 g of calcium HMB per bottle, twice a day for 12 weeks)
Trial: 35684144
Drug: HMB-free oral
RxNorm normalized name: Phillips' Cramp-free Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HMB-free oral nutritional supplement (similar composition devoid of HMB, twice a day for 12 weeks)
Trial: 35076302
Drug: Pavlik harness
RxNorm normalized name: HARNESS,PROREN UNDERGARMENT 2XL/3XL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pavlik harness treatment
Trial: 32558199
Drug: Belatacept maintenance
RxNorm normalized name: Belatacept
DrugBank: Belatacept (DB06681)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Belatacept maintenance therapy
Trial: 32558199
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group with rabbit antithymocyte globulin (rATG) induction, rapid steroid taper, and maintenance mycophenolate and tacrolimus
Trial: 32891161
Drug: Management of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Management of temporary suspension in clinical trials
Trial: 35101098
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of rocuronium bromide for 48 hours
Trial: 35343933
Drug: Subparaneural upper
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subparaneural upper trunk block (5 mL of 0.5% ropivacaine)
Trial: 35343933
Drug: Interscalene block
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interscalene block (15 mL of 0.5% ropivacaine)
Trial: 32702309
Drug: Pazopanib (350
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pazopanib (350 mg/m2 once daily for patients <18 years; 600 mg once daily for patients ≥18 years)
Trial: 33335310
Drug: JNJ-42165279 (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JNJ-42165279 (100 mg)
Trial: 32867830
Drug: Prescription of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prescription of biotherapy (rituximab, adalimumab, abatacept) using SinnoTest® software, a prediction software based on proteomic biomarkers.
Trial: 32867830
Drug: Prescription of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prescription of biotherapy based on current practice, without the SinnoTest® software (any biotherapy).
Trial: 33543797
Drug: Energy-dense formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Energy-dense formula (100 mL, 2 kcal/mL)
Trial: 33543797
Drug: Standard formula
RxNorm normalized name: Standard formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard formula (200 mL, 1 kcal/mL)
Trial: 32506227
Drug: FTL-assisted delivery
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FTL-assisted delivery of topical tranexamic acid (TXA)
Trial: 35940932
Drug: Iodophor solution
RxNorm normalized name: iodophors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iodophor solution
Trial: 34766389
Drug: M. officinalis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: M. officinalis capsules (400 mg/d; n = 23)
Trial: 35041636
Drug: Hydrocodone/acetaminophen 5/325
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrocodone/acetaminophen 5/325 mg
Trial: 35041636
Drug: Ibuprofen/acetaminophen 600/325
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen/acetaminophen 600/325 mg
Trial: 33197662
Drug: Peppermint oil
RxNorm normalized name: Peppermint Oil
DrugBank: Peppermint oil (DB11198)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peppermint oil applied three times a day for five days after chemotherapy in addition to routine antiemetic treatment.
Trial: 33197662
Drug: Routine antiemetic
RxNorm normalized name: metoclopramide
DrugBank: Metoclopramide (DB01233)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Routine antiemetic treatment only (Control group).
Trial: 35870902
Drug: Nebulized budesonide
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Nebulized budesonide combined with intravenous hydrocortisone hemisuccinate (n = 23)
Trial: 35870902
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline combined with intravenous hydrocortisone hemisuccinate (n = 27)
Trial: 34498068
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g IV acetaminophen every six hours for 48 hours postoperatively
Trial: 35818157
Drug: Subcutaneous immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous immunotherapy for pollen; 3 years of treatment.
Trial: 35818157
Drug: Sublingual immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual immunotherapy for grass pollen, house-dust mite, or Japanese cedar; duration not specified.
Trial: 35818157
Drug: Both sublingual
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both sublingual and subcutaneous grass pollen immunotherapies; 2 years of treatment.
Trial: 36364765
Drug: Drinking speed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drinking speed of 20 mL/5 min
Trial: 36364765
Drug: Drinking speed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drinking speed of 40 mL/5 min
Trial: 36364765
Drug: Drinking speed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drinking speed of 80 mL/5 min
Trial: 34428832
Drug: Vancomycin (7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vancomycin (7 days of oral intake)
Trial: 32565594
Drug: Vilazodone 20
RxNorm normalized name: vilazodone 20 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vilazodone 20 mg daily
Trial: 32565594
Drug: Amitriptyline 75
RxNorm normalized name: amitriptyline 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amitriptyline 75 mg daily
Trial: 33560411
Drug: i.v. ghrelin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. ghrelin administration
Trial: 33704530
Drug: standard induction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: standard induction chemotherapy
Trial: 33039693
Drug: Semaglutide (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Semaglutide (0.1 mg, 0.2 mg, 0.4 mg)
Trial: 34363051
Drug: Home-based transcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Home-based transcutaneous electrical acupoint stimulation (TEAS) for 12 weeks, 4 weekly sessions
Trial: 34363051
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care (continuation of antihypertensive drugs and lifestyle education)
Trial: 32639394
Drug: Ketotifen fumarate
RxNorm normalized name: Ketotifen Fumarate
DrugBank: Ketotifen (DB00920)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ketotifen fumarate (KF) 5 mg orally twice daily for 6 weeks
Trial: 32639394
Drug: Lactose placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactose placebo (PL) orally twice daily for 6 weeks
Trial: 33653754
Drug: Vibration therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vibration therapy coupled with protocolised mobilisation
Trial: 32024955
Drug: Osmotically controlled
RxNorm normalized name: nifedipine
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Osmotically controlled Eperisone 150 mg tablets
Trial: 32024955
Drug: Immediate release
RxNorm normalized name: Namenda, immediate release oral kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate release Eperisone tablets (reference formulation)
Trial: 34691212
Drug: DHEA (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHEA (25 mg orally 3 times a day for 90 days)
Trial: 32599738
Drug: Cereal A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cereal A (0% whole grain flour, high sugar content, 24 g/100 g)
Trial: 32599738
Drug: Cereal B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cereal B (50% whole grain flour, medium sugar content, 12 g/100 g)
Trial: 32777383
Drug: Intranasal oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal oxytocin treatment for 24 weeks
Trial: 35981270
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy (modified folinic acid-fluorouracil-oxaliplatin 6 or capecitabine-oxaliplatin) for 3 months followed by transanal excision surgery (TES)
Trial: 35981270
Drug: Transanal excision
RxNorm normalized name: pNF1-Blast Excised
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transanal excision surgery (TES) after chemotherapy
Trial: 35981270
Drug: Quality of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quality of life and rectal function scores
Trial: 32187464
Drug: Lopinavir-ritonavir (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lopinavir-ritonavir (400 mg and 100 mg, respectively) twice a day for 14 days, in addition to standard care
Trial: 35465733
Drug: trastuzumab +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: trastuzumab + chemotherapy (eribuline, capecitabine or vinorelbine)
Trial: 34582451
Drug: Ready-to-use supplementary
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ready-to-use supplementary food (RUSF) plus anti-infective therapies (azithromycin, more frequent IPTp, testing/treatment for vaginal dysbiosis)
Trial: 34582451
Drug: Ready-to-use supplementary
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ready-to-use supplementary food (RUSF) plus anti-infective therapies
Trial: 34582451
Drug: Standard of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care (blended corn/soy flour and intermittent preventive treatment for malaria in pregnancy)
Trial: 32216723
Drug: 10% Carbamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10% Carbamide gel
Trial: 32216723
Drug: Hydrogen peroxide
RxNorm normalized name: Hydrogen Peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydrogen peroxide gel
Trial: 33556381
Drug: Intravitreal aflibercept
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal aflibercept (IVT‐AFL) 2 mg at baseline and every 4 weeks thereafter
Trial: 35745116
Drug: Low-Carbohydrate Oral
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-Carbohydrate Oral Nutritional Supplement (LC-ONS)
Trial: 35745116
Drug: Standard Oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard Oral Nutritional Supplement (ST-ONS)
Trial: 33399934
Drug: novel adjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: novel adjuvant dendritic cell therapy with transfection of heat-shock protein 70 messenger RNA
Trial: 32783912
Drug: Oral immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral immunotherapy (OIT) for peanut allergies
Trial: 33183969
Drug: Symptom-palliating treatment
RxNorm normalized name: Pamprin Multi-Symptom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Symptom-palliating treatment
Trial: 33183969
Drug: Guideline-based treatments
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guideline-based treatments or guideline-based treatments in combination with non-guideline-based treatments
Trial: 33183969
Drug: Overall treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall treatment (guideline based or non-guideline based)
Trial: 32645162
Drug: Antiretroviral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiretroviral therapy (ART) regimens including nucleoside/nucleotide reverse‐transcriptase inhibitor (NRTI) plus nonnucleoside reverse‐transcriptase inhibitor (43%), NRTI plus integrase strand transfer inhibitor (25%), and NRTI plus protease inhibitor (19%).
Trial: 34490707
Drug: Minocycline 100
RxNorm normalized name: minocycline 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minocycline 100 mg once daily
Trial: 34490707
Drug: Clofazimine 100
RxNorm normalized name: clofazimine 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clofazimine 100 mg thrice daily
Trial: 36403976
Drug: Low-dose febuxostat
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose febuxostat (20 mg/day)
Trial: 36403976
Drug: Allopurinol (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allopurinol (200 mg/day)
Trial: 36403976
Drug: Low-dose febuxostat
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose febuxostat
Trial: 33449480
Drug: Promethazine sensitization
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Promethazine sensitization via oral exposure
Trial: 32596393
Drug: Tripterygium glycosides
RxNorm normalized name: anthraquinone glycoside
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tripterygium glycosides from Tripterygium wilfordii Hook F (TwHF) combined with angiotensin receptor blocker (ARB)
Trial: 32596393
Drug: Angiotensin receptor
RxNorm normalized name: Angiotensin receptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Angiotensin receptor blocker (ARB) only
Trial: 35899486
Drug: Microneedling with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Microneedling with topical irradiated amniotic collagen matrix (IACM)
Trial: 35899486
Drug: Microneedling with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Microneedling with topical platelet rich plasma (PRP)
Trial: 32000167
Drug: Preoperative chemotherapy
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative chemotherapy (fluorouracil, leucovorin calcium, doxorubicin, cyclophosphamides/granulocyte colony-stimulating factor)
Trial: 32000167
Drug: Postoperative chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative chemotherapy (fluorouracil, leucovorin calcium, doxorubicin, cyclophosphamides/granulocyte colony-stimulating factor)
Trial: 32050061
Drug: Polymer-free drug-coated
RxNorm normalized name: dicresulene polymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polymer-free drug-coated stents
Trial: 32829105
Drug: Bevacizumab plus
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab plus FOLFIRI with UGT1A1 genotyping and irinotecan dose escalation
Trial: 32829105
Drug: Dose escalation
RxNorm normalized name: PALFORZIA Initial Dose Escalation KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose escalation of irinotecan based on UGT1A1 genotyping
Trial: 33840246
Drug: Subcutaneous tunneling
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous tunneling technique
Trial: 33388289
Drug: Pre-hospital tirofiban
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-hospital tirofiban administration
Trial: 33057314
Drug: IV2 (two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV2 (two intravenous doses of 15 mg TXA/kg: prior to skin incision and 6 hours after the first dose)
Trial: 33057314
Drug: TOP (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TOP (2 g TXA in 50 mL of saline irrigated topically at the end of the surgery)
Trial: 35429481
Drug: Night-time subcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Night-time subcutaneous apomorphine infusion (up to 5 mg/h)
Trial: 35429481
Drug: Night-time subcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Night-time subcutaneous apomorphine infusion
Trial: 33067919
Drug: Low-dose mindfulness-based
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose mindfulness-based intervention (MBI) - weekly 1-hour mindfulness training over 4 weeks
Trial: 35616850
Drug: Thymosin α1
RxNorm normalized name: chymosin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thymosin α1 (Tα1) treatment
Trial: 35300599
Drug: Patient-initiated treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient-initiated treatment model for HFS and BEB using botulinum toxin type A (BoNT/A) with self-determined treatment schedule for 9 months.
Trial: 35300599
Drug: Patient-initiated treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient-initiated treatment model for HFS and BEB.
Trial: 33633036
Drug: DOR/3TC/TDF (once-daily)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DOR/3TC/TDF (once-daily)
Trial: 35014061
Drug: BAY 2433334
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BAY 2433334 (25/50/100 mg once daily)
Trial: 35014061
Drug: BAY 2433334
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BAY 2433334 (25 mg twice daily)
Trial: 35014061
Drug: BAY 2433334
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BAY 2433334 (75 mg once daily)
Trial: 32852548
Drug: Open-loop therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Open-loop therapy (OL)
Trial: 36910347
Drug: Drotaverine hydrochloride
RxNorm normalized name: drotaverine hydrochloride
DrugBank: Drotaverine (DB06751)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drotaverine hydrochloride (40mg, 2 ml intravenous)
Trial: 36910347
Drug: Placebo (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (2 ml Vitamin B complex)
Trial: 33980033
Drug: Botulinum toxin
RxNorm normalized name: Botulinum toxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum toxin Type A (BTX‐A) injection